Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients.
Keunecke
C
C
Division of Transplant Surgery, Department of Surgery, Medical Centre (Grosshadern), University of Munich, Munich, Germany.
Rothenpieler
U
U
Zanker
B
B
Schneeberger
H
H
Illner
W D
WD
Theodorakis
J
J
Stangl
M
M
Land
W
W
D000328:Adult; D001161:Arteriosclerosis / Q000517:prevention & control; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010865:Pilot Projects; D012449:Safety
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid